Among adults with Type2Diabetes and liver cirrhosis, SGLT2 inhibitor use was associated with lower risks of end-stage kidney disease, cardiovascular events, mortality, and hepatic decompensation compared with DPP4 inhibitors.
Importance Type 2 diabetes (T2D) and liver cirrhosis frequently coexist, creating a high-risk population for adverse outcomes. Patients with both conditions face elevated risks of kidney and cardiovascular complications, yet evidence regarding optimal antidiabetic therapy in this vulnerable population remains limited.
Objective To evaluate the association of sodium-glucose cotransporter–2 inhibitor (SGLT2i) vs dipeptidyl peptidase–4 inhibitor (DPP4i) use with kidney outcomes, cardiovascular events, and hepatic decompensation in patients with concurrent T2D and liver cirrhosis.
Design, Setting, and Participants This nationwide retrospective cohort study utilized data from the Taiwan’s National Health Insurance Database between May 2016 and December 2023. Adults with both T2D and liver cirrhosis who initiated either SGLT2is or DPP4is were included.